The purpose of this study was to investigate the frequency of @entity876 overexpression in the primary @entity43 of @entity1 with @entity5 (SBTs) and to determine the relationship between @entity876 overexpression and risk of progression/recurrence and survival. Of 112 @entity1 with stages II-IV SBTs, @entity982 -embedded tissue from the primary @entity43 was available in 68 cases. Immunohistochemical staining for @entity876 was performed. Clinical information was abstracted from the medical records. The major end points selected for analysis were time to progression/relapse, disease-free survival, overall survival, and cause-specific survival. Univariate and multivariate regression analyses were also performed. The median @entity1 age was 37 years (range, 17-67 years). Twenty-two @entity1 had @entity34 , and 46 had @entity5 . The mean follow-up time was 105 months. Nineteen @entity1 (28%) had either disease progression (1 @entity1 ) or relapse (18 @entity1 ). Eleven @entity1 died: 10 @entity1 died of their @entity5 , and 1 @entity1 died of other causes. Thirteen cases (19%) had positive immunostaining for @entity876 . Overexpression of @entity876 was significantly associated with an increased probability of progression/recurrence (P = 0.005) and a decreased overall survival (P = 0.012). After adjusting for age, International Federation of Gynecology and Obstetrics (FIGO) stage, the presence of @entity41 , and the presence of invasive implants, @entity1 whose @entity5 overexpressed @entity876 had a 4-fold increased risk of progression/ recurrence. Similarly, @entity1 whose @entity5 overexpressed @entity876 had an approximately 6-fold increased risk of death. @entity876 overexpression in the @entity43 of @entity1 with stage II and III SBTs is significantly associated with increased probability of relapse and decreased overall survival. This information should provide better prognostic data to @entity1 and their families and allow us to select @entity1 who might benefit from postoperative treatment.

Prognostic significance of XXXX expression in @entity43 .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian tumors', 'ovarian tumor'] @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'stage III disease', 'stages II and III serous borderline tumors', 'tumors'] @entity876 :: ('7157', 'Gene') :: ['p53'] @entity982 :: ('MESH:D010232', 'Chemical') :: ['paraffin'] @entity34 :: ('MESH:D016609', 'Disease') :: ['stage II disease']
@entity876 :: (7157,Gene) :: ['p53']
